Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Blueprint Medicines has entered into collaboration with Alexion to discover, develop and commercialize new drug candidates for an undisclosed activated kinase target, the main cause of a rare genetic disease.
Subscribe to our email newsletter
Under the deal, Blueprint will identify and optimize drug candidates using its kinase-focused drug discovery platform.
The company will also conduct all research activities before filing an investigational new drug (IND) application with the US Food and Drug Administration (FDA).
The deal will see Alexion develop and commercialize Blueprint Medicines’ drug candidates.
Blueprint Medicines chief executive officer Jeffrey Albers said: "Our kinase-focused platform, which integrates a novel target discovery engine and a proprietary compound library, enables us to craft highly selective kinase drugs for genomic drivers of disease across many therapeutic areas."
Blueprint will be eligible to will receive an upfront payment of $15m, more than $250m in payments upon the successful achievement of pre-specified preclinical, clinical, regulatory and commercial milestones.
Additionally, Blueprint will be eligible to receive royalty payments following the commercialization of the product.
Alexion executive vice president and Research and Development global head Martin Mackay said: "Blueprint Medicines’ unique discovery platform enables it to create drug candidates for extremely challenging kinase targets.
"Even in these early stages, Blueprint Medicines’ compounds show impressive selectivity toward the mutant kinase, thereby sparing other kinases and delivering drug to the specified target."